About the Conference

The fields of liquid biopsy and immuno-oncology are coming together as the pace of discovery of new targets and innovativetreatments are ramping up and requiring novel biomarkers to predict which patients will be respond to treatment, minimize toxicity and monitor therapy. A wide range of new circulating biomarkers are being discovered and they will be vetted for their suitability for assays and use in the clinical setting. Immunotherapy advances include an expanding array of T-cell engineering approaches, next generation molecules and companion diagnostics to guide treatment decisions.


Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean